TEL
AVIV, Israel, April 19,
2023 /PRNewswire/ -- Chemomab Therapeutics Ltd.
(Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company
focused on the discovery and development of innovative therapeutics
for fibro-inflammatory diseases with high unmet need, today
announced that the company will participate in a number of
scientific conferences in April and May.
British Society for Rheumatology Annual Conference –
April 24-26, 2023
Date:
|
April 24,
2023
|
Time:
|
9:45am BST
|
Venue:
|
Manchester Central
Convention Complex, Manchester, UK and virtual
|
Format:
|
Oral presentation:
CCL24 Serum Concentration Predicts Both Vascular and Fibrotic
Complications in Systemic Sclerosis: Rationale for a Biological
Target Driven, Basket Trial Across Disease Subsets
|
Presenter:
|
Professor Enrico De
Lorenzis, Leeds Institute of Rheumatic and Musculoskeletal
Diseases, University of Leeds, UK
|
Information:
|
https://www.rheumatology.org.uk/events-learning/conferences/annual-conference
|
EASL Monothematic Conference on Biliary Fibrosis 2023 –
May 12-13, 2023
Date:
|
May 12, 2023
|
Time:
|
17:20-17:50
CEST
|
Venue:
|
Grand Hotel Baglioni,
Florence, Italy
|
Format:
|
Poster presentation:
Patient proteomic data and mouse model reinforce the
proinflammatory role of CCL24 in cholestatic disease
|
Session:
|
ePoster session 3 and
break
|
Presenter:
|
Matt Frankel, MD, Chief
Medical Officer, Chemomab
|
Information:
|
https://easl.eu/event/biliary-fibrosis-23/
|
In addition, Chemomab's corporate development team will be in
Boston June
5-8, 2023, participating in the BIO International
Convention's One-on-One Partnering™ event. Registered attendees
can click here to log in and schedule a meeting with
Chemomab.
About Chemomab Therapeutics
Chemomab is a clinical stage biotechnology company discovering
and developing innovative therapeutics for fibro-inflammatory
diseases with high unmet need. Based on the unique and pivotal role
of the chemokine CCL24 in promoting fibrosis and inflammation,
Chemomab developed CM-101, a monoclonal antibody designed to
neutralize CCL24 activity. In preclinical and clinical studies to
date, CM-101 appears safe, with the potential to treat multiple
severe and life-threatening fibro-inflammatory diseases.
Encouraging results from a Phase 2 biomarker study in NASH patients
and an investigator study in patients with severe lung injury were
recently reported. A Phase 2 trial in primary sclerosing
cholangitis patients is ongoing and a Phase 2 systemic sclerosis
trial is expected to begin around midyear. For more information on
Chemomab, visit chemomab.com.
Contacts:
Investors:
|
Investors & Media:
|
Irina Koffler
|
Barbara
Lindheim
|
LifeSci Advisors,
LLC
|
Chemomab
Therapeutics
|
Phone: +1 (917)
734-7387
|
Consulting Vice
President, Investor & Public Relations
|
ir@chemomab.com
|
Strategic
Communications
|
|
barbara.lindheim@chemomab.com
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/chemomab-therapeutics-to-present-at-upcoming-scientific-conferences-301801509.html
SOURCE Chemomab Therapeutics, Ltd.